Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 30, Issue 1, 2016, Pages 59-77

  Modlin, Irvin M ^a   Bodei, Lisa ^b   Kidd, Mark ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Wren Laboratories   (United States)

Author keywords

biomarker; carcinoid; chromogranin A; circulating tumor cells (CTC); miRNA; monoanalyte; multianalyte; NETest; neuroendocrine tumor; PCR

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; BIOLOGICAL MARKER; CHROMOGRANIN; CHROMOGRANIN A; CHROMOGRANIN B; CONNECTIVE TISSUE GROWTH FACTOR; INSULIN; MICRORNA; NEURON SPECIFIC ENOLASE; PANCREAS POLYPEPTIDE; PANCREASTATIN; PROGASTRIN RELEASING PEPTIDE; SECRETOGRANIN II; SEROTONIN; TACHYKININ; TUMOR MARKER;

ALGORITHM; ARTICLE; CANCER GENETICS; CANCER PROGNOSIS; CANCER SCREENING; CIRCULATING TUMOR CELL; GENETIC ANALYSIS; HUMAN; NATIONAL HEALTH ORGANIZATION; NEUROENDOCRINE TUMOR; SOMATIC MUTATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; BLOOD; EARLY CANCER DIAGNOSIS; METABOLISM; NEUROENDOCRINE TUMORS; PROCEDURES; STANDARDS;

ALGORITHMS; BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; HUMANS; MICRORNAS; NEUROENDOCRINE TUMORS;

EID: 84959890838     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2016.01.002     Document Type: Review

References (100)

1. J.D. Brooks Translational genomics: the challenge of developing cancer biomarkers Genome Res 22 2012 183 187
2. I. Modlin, I. Drozdov, D. Alaimo, and et al. A multianalyte pcr blood test outperforms single analyte elisas for neuroendocrine tumor detection Endocr Relat Cancer 21 2014 615 628
3. I. Modlin, I. Drozdov, and M. Kidd The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood PLoS One 2013 e63364
4. I. Modlin, I. Drozdov, and M. Kidd Gut neuroendocrine tumor blood qpcr fingerprint assay: characteristics and reproducibility Clin Chem 52 2014 419 429
5. U. McDermott, J.R. Downing, and M.R. Stratton Genomics and the continuum of cancer care N Engl J Med 364 2011 340 350 doi:310.1056/NEJMra0907178
6. L. Bodei, A. Sundin, M. Kidd, and et al. The status of neuroendocrine tumor imaging: from darkness to light? Neuroendocrinology 101 2015 1 17
7. J.G. Paez, P.A. Janne, J.C. Lee, and et al. Egfr mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 Epub 2004 Apr 1429
8. I. Gayed, T. Vu, R. Iyer, and et al. The role of 18f-fdg pet in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors J Nucl Med 45 2004 17 21
9. B. Hulka Overview of biological markers B. Hulka, J. Griffith, T. Wilcosky, Biological markers in epidemiology 1990 Oxford University Press New York 3 15
10. R. Frank, and R. Hargreaves Clinical biomarkers in drug discovery and development Nat Rev Drug Discov 2 2003 566 580
11. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674 doi:610.1016/j.cell.2011.02.013
12. M. Garcia-Closas, P. Hall, H. Nevanlinna, and et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics PLoS Genet 4 2008 e1000054 doi:1000010.1001371/journal.pgen.1000054
13. L.A. Kiemeney, S. Thorlacius, P. Sulem, and et al. Stefansson K: sequence variant on 8q24 confers susceptibility to urinary bladder cancer Nat Genet 40 2008 1307 1312 doi:1310.1038/ng. 1229, Epub 2008 Sep. 1314
14. H. Song, S.J. Ramus, J. Tyrer, and et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2 Nat Genet 41 2009 996 1000 doi:1010.1038/ng. 1424, Epub 2009 Aug 1002
15. Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615 doi:610.1038/nature10166
16. S.M. Dong, G. Traverso, C. Johnson, and et al. Detecting colorectal cancer in stool with the use of multiple genetic targets J Natl Cancer Inst 93 2001 858 865
17. M.O. Hoque, S. Begum, O. Topaloglu, and et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer Cancer Res 64 2004 5511 5517
18. M.O. Hoque, Q. Feng, P. Toure, and et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer J Clin Oncol 24 2006 4262 4269 Epub 2006 Aug 4214
19. O. Topaloglu, M.O. Hoque, Y. Tokumaru, and et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer Clin Cancer Res 10 2004 2284 2288
20. J. Chen, C. Rocken, C. Lofton-Day, and et al. Molecular analysis of apc promoter methylation and protein expression in colorectal cancer metastasis Carcinogenesis 2005 26 Sep 2016 37 43 Epub 2004
21. S.S. Salami, F. Schmidt, B. Laxman, and et al. Combining urinary detection of tmprss2: Erg and pca3 with serum psa to predict diagnosis of prostate cancer Urol Oncol 31 2013 566 571 doi:510.1016/j.urolonc.2011.1004.1001. Epub 2011 May 1019
22. M.A. Lewis, and J.C. Yao Molecular pathology and genetics of gastrointestinal neuroendocrine tumours Curr Opin Endocrinol Diabetes Obes 4 2013 4
23. B. Lawrence, B.I. Gustafsson, A. Chan, and et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors Endocrinol Metab Clin North Am 40 2011 1 18
24. T. Reya, S.J. Morrison, M.F. Clarke, and et al. Stem cells, cancer, and cancer stem cells Nature 414 2001 105 111
25. P.J. Stephens, C.D. Greenman, B. Fu, and et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development Cell 144 2011 27 40 10.1016/j.cell.2010.1011.1055
26. C.L. Chaffer, and R.A. Weinberg A perspective on cancer cell metastasis Science 331 2011 1559 1564 doi:1510.1126/science.1203543
27. M.S. Pepe An interpretation for the roc curve and inference using glm procedures Biometrics 56 2000 352 359
28. D.E. Shapiro The interpretation of diagnostic tests Stat Methods Med Res 8 1999 113 134
29. R. Parikh, A. Mathai, S. Parikh, and et al. Understanding and using sensitivity, specificity and predictive values Indian J Ophthalmol 56 2008 45 50
30. V.L. Tsikitis, B.C. Wertheim, and M.A. Guerrero Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the united states: a seer analysis J Cancer 3 2012 292 302
31. M. Duque, I.M. Modlin, A. Gupta, and et al. Biomarkers in neuroendocrine tumors JOP J Pancreas 14 2013 372 376
32. K. Oberg, I. Modlin, W. DeHerder, and et al. Biomarkers for neuroendocrine tumor disease: a delphic consensus assessment of multianalytes, genomics, circulating cells and monoanalytes Lancet Oncol 16 2015 e435 e446
33. M. Stridsberg, B. Eriksson, K. Oberg, and et al. A comparison between three commercial kits for chromogranin a measurements J Endocrinol 177 2003 337 341
34. C.N. Reid, M. Stevenson, F. Abogunrin, and et al. Standardization of diagnostic biomarker concentrations in urine: the hematuria caveat PLoS One 7 2012
35. M. Sang, X. Wu, X. Fan, and et al. Multiple mage-a genes as surveillance marker for the detection of circulating tumor cells in patients with ovarian cancer. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals 19 2014 34 42
36. M. Chadeau-Hyam, R.C. Vermeulen, D.G. Hebels, and et al. Prediagnostic transcriptomic markers of chronic lymphocytic leukemia reveal perturbations 10 years before diagnosis Ann Oncol 25 2014 1065 1072 doi:1010.1093/annonc/mdu1056. Epub 2014 Feb 1020
37. G.S. Firestein A biomarker by any other name Nat Clin Pract Rheumatol 2 2006 635
38. V. Marotta, V. Nuzzo, T. Ferrara, and et al. Limitations of chromogranin a in clinical practice Biomarkers 17 2012 186 191 doi:110.3109/1354750X.1352012.1654511. Epub 1352012 Feb 1354756
39. I.M. Modlin, B.I. Gustafsson, S.F. Moss, and et al. Chromogranin a - biological function and clinical utility in neuro endocrine tumor disease Ann Surg Oncol 17 2010 2427 2443
40. K.H. Jensen, L. Hilsted, C. Jensen, and et al. Chromogranin a is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors Scand J Gastroenterol 48 2013 70 77 10.3109/00365521.00362012.00733953 Epub 00362012 Oct 00365524
41. M.C. Zatelli, M. Torta, A. Leon, and et al. Italian CromaNet Working G: chromogranin a as a marker of neuroendocrine neoplasia: an Italian multicenter study Endocr Relat Cancer 14 2007 473 482
42. I.M. Modlin, K. Oberg, D.C. Chung, and et al. The current status of gastroenteropancreatic neuroendocrine tumors Lancet Oncol 9 2008 61 72
43. I.M. Modlin, I. Latich, M. Zikusoka, and et al. Gastrointestinal carcinoids: the evolution of diagnostic strategies J Clin Gastroenterol 40 2006 572 582
44. G. Kanakis, and G. Kaltsas Biochemical markers for gastroenteropancreatic neuroendocrine tumours (gep-nets) Best Pract Res Clin Gastroenterol 26 2012 791 802 doi:710.1016/j.bpg.2012.1012.1006
45. J.T. Wu, A.J. Erickson, K.C. Tsao, and et al. Elevated serum chromogranin a is detectable in patients with carcinomas at advanced disease stages Ann Clin Lab Sci 30 2000 175 178
46. A. Sciarra, S. Monti, V. Gentile, and et al. Chromogranin a expression in familial versus sporadic prostate cancer Urology 66 2005 1010 1014
47. R.J. Hsiao, M.S. Mezger, and D.T. O'Connor Chromogranin a in uremia: progressive retention of immunoreactive fragments Kidney Int 37 1990 955 964
48. C.S. Jianu, R. Fossmark, U. Syversen, and et al. A meal test improves the specificity of chromogranin a as a marker of neuroendocrine neoplasia Tumour Biol 31 2010 373 380 Epub 2010 May 2018
49. B. Lawrence, B.I. Gustafsson, M. Kidd, and et al. The clinical relevance of chromogranin a as a biomarker for gastroenteropancreatic neuroendocrine tumors Endocrinol Metab Clin North Am 40 2011 111 134 viii. doi:110.1016/j.ecl.2010.1012.1001
50. P. de Souto Barreto, M. Lapeyre-Mestre, C. Mathieu, and et al. Prevalence and associations of the use of proton-pump inhibitors in nursing homes: a cross-sectional study J Am Med Dir Assoc 14 2013 265 269 doi:210.1016/j.jamda.2012.1010.1018. Epub 2012 Dec 1011
51. L.B. Gerson, P.J. Kahrilas, and R. Fass Insights into gastroesophageal reflux disease-associated dyspeptic symptoms Clin Gastroenterol Hepatol 9 2011 824 833 doi:810.1016/j.cgh.2011.1005.1015. Epub 2011 May 1020
52. D. Campana, F. Nori, L. Piscitelli, and et al. Chromogranin a: is it a useful marker of neuroendocrine tumors? JCO 25 2007 1967 1973
53. M. Stridsberg, K. Oberg, Q. Li, and et al. Measurements of chromogranin a, chromogranin b (secretogranin i), chromogranin c (secretogranin ii) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours J Endocrinol 144 1995 49 59
54. K. Calhoun, S. Toth-Fejel, J. Cheek, and et al. Serum peptide profiles in patients with carcinoid tumors Am J Surg 186 2003 28 31
55. D. Raines, M. Chester, A.E. Diebold, and et al. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans Pancreas 41 2012 508 511 doi:510.1097/MPA.1090b1013e318243a318240b318246
56. T. Ito, H. Igarashi, and R.T. Jensen Serum pancreastatin: the long sought for universal, sensitive, specific tumor marker for neuroendocrine tumors (nets)? Pancreas 41 2012 505 507
57. G.B. Turner, B.T. Johnston, D.R. McCance, and et al. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours Gut 55 2006 1586 1591
58. E.G. Siegel, B. Gallwitz, U.R. Folsch, and et al. Effect of human pancreastatin peptide (hp-16) on oral glucose tolerance in man Exp Clin Endocrinol Diabetes 106 1998 178 182
59. G.R. Valicherla, Z. Hossain, S.K. Mahata, and et al. Pancreastatin is an endogenous peptide that regulates glucose homeostasis Physiol Genomics 45 2013 1060 1071 doi:1010.1152/physiolgenomics.00131.02013. Epub 02013 Sep. 00124
60. A. Bergenfelz, L. Luts, T.B. Jensen, and et al. Pancreastatin plasma levels in patients with primary hyperparathyroidism World J Surg 24 2000 1579 1583
61. T.M. O'Dorisio, S.R. Krutzik, E.A. Woltering, and et al. Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior Pancreas 39 2010 611 616 doi:610.1097/MPA.1090b1013e3181c1068d1097a
62. J.M. Conlon Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors Regul Pept 165 2010 5 11 10.1016/j.regpep.2009.1011.1013 Epub 2009 Nov 1026
63. P.R. Bech, N.M. Martin, R. Ramachandran, and et al. The biochemical utility of chromogranin a, chromogranin b and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia Ann Clin Biochem 51 2014 8 21 10.1177/0004563213489670 Epub 0004563213482013 Aug 0004563213489612
64. S. Bhattacharyya, A. Jagroop, D.M. Gujral, and et al. Circulating plasma and platelet 5-hydroxytryptamine in carcinoid heart disease: a pilot study J Heart Valve Dis 22 2013 400 407
65. E. Bajetta, L. Ferrari, A. Martinetti, and et al. Chromogranin a, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors Cancer 86 1999 858 865
66. M.R. Tellez, G. Mamikunian, T.M. O'Dorisio, and et al. A single fasting plasma 5-hiaa value correlates with 24-hour urinary 5-hiaa values and other biomarkers in midgut neuroendocrine tumors (nets) Pancreas 42 2013 405 410
67. R. Dobson, M.I. Burgess, M. Banks, and et al. The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study PLoS One 8 2013
68. E. Baudin, A. Gigliotti, M. Ducreux, and et al. Neuron-specific enolase and chromogranin a as markers of neuroendocrine tumours Br J Cancer 78 1998 1102 1107
69. B. Eriksson, K. Oberg, and M. Stridsberg Tumor markers in neuroendocrine tumors Digestion 62 Suppl. 1 2000 33 38
70. H.N. Langstein, J.A. Norton, V. Chiang, and et al. The utility of circulating levels of human pancreatic polypeptide as a marker for islet cell tumors Surgery 108 1990 1109 1115 discussion 1115-1116
71. T. Walter, L. Chardon, X. Chopin-laly, and et al. Is the combination of chromogranin a and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? Eur J Cancer 48 2012 1766 1773
72. J.M. Feldman, and T.M. O'Dorisio Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors Am J Med 81 1986 41 48
73. C.M. Korse, B.G. Taal, J.M. Bonfrer, and et al. An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival Ann Oncol 22 2011 2625 2630 doi:2610.1093/annonc/mdr2007. Epub 2011 Mar 2617
74. C.M. Korse, B.G. Taal, CAd Groot, and et al. Chromogranin-a and n-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor JCO 27 2009 4293 4299
75. M. Behnes, M. Brueckmann, S. Lang, and et al. Connective tissue growth factor (ctgf/ccn2): diagnostic and prognostic value in acute heart failure Clin Res Cardiol 103 2014 107 116 doi:110.1007/s00392-00013-00626-00396. Epub 02013 Oct 00322
76. D.S. Bergestuen, J. Gravning, K.H. Haugaa, and et al. Plasma ccn2/connective tissue growth factor is associated with right ventricular dysfunction in patients with neuroendocrine tumors BMC Cancer 10 2010 6
77. M.S. Khan, A. Kirkwood, T. Tsigani, and et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors J Clin Oncol 31 2013 365 372 doi:310.1200/JCO.2012.1244.2905. Epub 2012 Dec 1217
78. M.S. Khan, T. Tsigani, M. Rashid, and et al. Circulating tumor cells and epcam expression in neuroendocrine tumors Clin Cancer Res 17 2011 337 345 Epub 2011 Jan 2011
79. J.M. Kinross, P. Drymousis, B. Jimenez, and et al. Metabonomic profiling: a novel approach in neuroendocrine neoplasias Surgery 154 2013 1185 1192 discussion 1192-1183
80. T. Cui, M. Hurtig, G. Elgue, and et al. Paraneoplastic antigen ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors PLoS One 5 2010 e16010
81. I.M. Modlin, S.F. Moss, D.C. Chung, and et al. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors J Natl Cancer Inst 100 2008 1282 1289 Epub 2008 Sep. 1289
82. I.M. Modlin, I. Drozdov, L. Bodei, and et al. Blood transcript analysis and metastatic recurrent small bowel carcinoid management BMC Cancer 14 2014 564 10.1186/1471-2407-1114-1564
83. M. Kidd, I.M. Modlin, and I. Drozdov Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors BMC Genomics 15 2014 595 10.1186/1471-2164-1115-1595
84. I.M. Modlin, H. Aslanian, L. Bodei, and et al. A pcr blood test outperforms chromogranin a in carcinoid detection and is unaffected by ppis Endocr Connect 14 2014 14 0100
85. I.M. Modlin, M. Kidd, L. Bodei, and et al. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract Am J Gastroenterol 110 2015 1223 1232 doi:1210.1038/ajg.2015.1160. Epub 2015 Jun 1222
86. M. Kidd, I. Drozdov, and I. Modlin Blood and tissue net gene cluster analysis correlate, define hallmarks and predict disease status Endocr Relat Cancer 22 2015 561 575
87. I. Modlin, I. Drozdov, and M. Kidd A multitranscript blood neuroendocrine tumor molecular signature to identify treatment efficacy and disease progress J Clin Oncol 31 Suppl. 2013 A4137
88. I. Modlin, A. Frilling, R. Salem, and et al. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of surgical resection and ablation strategies Surgery 159 1 2016 336 347
89. L. Bodei, M. Kidd, I.M. Modlin, and et al. Gene transcript analysis blood values correlate with (68)ga-dota-somatostatin analog (ssa) pet/ct imaging in neuroendocrine tumors and can define disease status Eur J Nucl Med Mol Imaging 42 2015 1341 1352 doi:1310.1007/s00259-00015-03075-00259. Epub 02015 May 00257
90. I. Modlin, M. Kidd, A. Taylor, and et al. Neuroendocrine tumor biomarkers: current status and perspectives Neuroendocrinology 100 2014 265 277
91. M. Cristofanilli, D.F. Hayes, G.T. Budd, and et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer J Clin Oncol 23 2005 1420 1430
92. S.J. Cohen, C.J. Punt, N. Iannotti, and et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer J Clin Oncol 26 2008 3213 3221
93. L. Resel Folkersma, L. San Jose Manso, I. Galante Romo, and et al. Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer Urology 10 2012 01049-01047
94. G. Di Leva, and C.M. Croce Mirna profiling of cancer Curr Opin Genet Dev 23 2013 3 11 10.1016/j.gde.2013.1001.1004 Epub 2013 Mar 1014
95. C. Roldo, E. Missiaglia, J.P. Hagan, and et al. Microrna expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior J Clin Oncol 24 2006 4677 4684 Epub 2006 Sep. 4611
96. C. Thorns, C. Schurmann, N. Gebauer, and et al. Global microrna profiling of pancreatic neuroendocrine neoplasias Anticancer Res 34 2014 2249 2254
97. A. Li, J. Yu, H. Kim, and et al. Microrna array analysis finds elevated serum mir-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls Clin Cancer Res 19 2013 3600 3610 doi:3610.1158/1078-0432.CCR-3612-3092. Epub 2013 May 3622
98. S.C. Li, A. Essaghir, C. Martijn, and et al. Global microrna profiling of well-differentiated small intestinal neuroendocrine tumors Mod Pathol 26 2013 685 696 doi:610.1038/modpathol.2012.1216. Epub 2013 Jan 1018
99. Gounden V, Zhao Z. Micrornas as potential biomarkers: is the future here? NACB - Scientific Shorts.
100. J.R. Prensner, and A.M. Chinnaiyan The emergence of lncrnas in cancer biology Cancer Discov 1 2011 391 407 doi:310.1158/2159-8290.CD-1111-0209